Alexis Ramírez Hernández

Tumor adaptation and therapeutic resistance represent major limitations to sustained treatment efficacy in modern oncology. Despite advances in targeted therapies and personalized approaches, disease progression and relapse remain frequent, reflecting the intrinsic biological complexity of malignant tumors. This review synthesizes high-impact evidence addressing the mechanisms that drive tumor adaptation under therapeutic pressure, with particular emphasis on intratumoral heterogeneity, evolutionary dynamics, and cellular plasticity. The analyzed literature supports the view of cancer as a dynamic and evolving ecosystem composed of genetically and phenotypically diverse subpopulations that respond heterogeneously to treatment. Resistance emerges as a predictable consequence of Darwinian selection, shaped by both genetic alterations and non-genetic adaptive processes, including reversible drug-tolerant states and microenvironmental influences. The findings further highlight the limitations of static, single-time-point molecular profiling in capturing tumor complexity and guiding long-term therapeutic decisions. Evolution-informed strategies, such as adaptive therapy and rational treatment sequencing, are discussed as biologically grounded approaches that may improve disease control by managing, rather than attempting to eradicate, heterogeneous tumor populations. This integrative perspective is particularly relevant for diverse healthcare settings, including those in Latin America, where conceptual frameworks can support clinical decision-making in variable resource contexts. Overall, understanding tumor adaptation and resistance as emergent evolutionary phenomena provides a coherent foundation for advancing personalized oncology, improving clinical reasoning, and strengthening oncology education

The gut microbiota has emerged as a key modulator of drug metabolism, efficacy, and toxicity, adding a critical layer of complexity to pharmacological processes traditionally attributed solely to host physiology. In hepatobiliary disease, this interaction acquires particular relevance due to alterations in bile acid metabolism, intestinal barrier function, immune regulation, and enterohepatic circulation. This review synthesizes current evidence on microbiota–drug interactions within hepatobiliary contexts, integrating mechanistic, translational, and clinical data to provide a coherent pharmacological framework. The analyzed literature consistently demonstrates that intestinal microorganisms can directly biotransform xenobiotics, modify effective bioavailability, and generate metabolites with altered pharmacodynamic or toxicological properties. In parallel, microbial modulation of bile acid pools and signaling pathways indirectly influences hepatic drug-metabolizing enzymes, transporters, and inflammatory responses. The reciprocal capacity of drugs to reshape microbial composition further contributes to dynamic and time-dependent variability in drug exposure. Collectively, these mechanisms help explain interindividual differences in therapeutic response and susceptibility to adverse drug reactions that are frequently observed in hepatobiliary disease but remain insufficiently accounted for by conventional dosing paradigms. By consolidating these findings, this review highlights the gut microbiota as an integral component of hepatobiliary pharmacology and underscores its relevance for advancing more precise, individualized, and safer therapeutic strategies.

The present multinational study evaluated the comprehensive metabolic, cardiovascular, renal, and hepatic effects of incretin-based therapies in adults with obesity and type 2 diabetes mellitus (T2DM) across Mexico, Colombia, and Ecuador. After 12 months of treatment, participants exhibited consistent and clinically significant improvements in all outcome domains. Mean body weight decreased by 10.7%, HbA1c by 1.3 percentage points, and fasting glucose by 23.5%, accompanied by favorable reductions in blood pressure and lipid levels. Estimated glomerular filtration rate (eGFR) improved (+2.3 mL/min/1.73 m²), while albuminuria declined (−14 mg/g), reflecting strong renal protection. Hepatic parameters, including ALT, CAP score, and fibrosis indices (FIB-4, NFS), also improved, suggesting regression of steatosis and early fibrosis. The incidence of major adverse cardiovascular events (MACE) was 2.6%, with no significant differences between countries (p > 0.05), confirming regional reproducibility. Collectively, these findings demonstrate that incretin-based pharmacotherapy provides integrated metabolic and multiorgan protection, in line with evidence from pivotal trials such as STEP, SURPASS, SELECT, and FLOW. The uniform outcomes across nations highlight its potential scalability in Latin America, supporting incorporation into regional health programs for diabetes, obesity, and metabolic dysfunction–associated steatotic liver disease (MASLD). Incretin-based therapies therefore represent a transformative paradigm in modern endocrinology—uniting glycemic control, weight management, and organ preservation under a single therapeutic strategy.